Ipsirius has established a broad patent estate covering the use of pluripotent stem cells, their derivatives and components as the basis for polyvalent universal cancer vaccines.
Our research has shown that there are a broad number of immunogenic antigens which are found on both cancer stem cells and pluripotent stem cells. This overlap in antigen expression is the basis for our innovative therapy.
As pluripotent stem cells are « immortal”, they can be produced vast quantities in cGMP conditions suitable for clinical use. Furthermore, the initial stem cell populations can be genetically modified to enhance functional properties for a specific therapeutic use. This is the basis of the proprietary procedure of IPSIRIUS to engineer in vitro pluripotent-stem cell based embryonic gene-expressing cancer vaccines.
While developing our first product, IPVAC 1.0, which will target a broad range of cancers, our research is continuing to develop additional products which will target specific cancers.